Sign in
Enrolling by invitationPhase 2/3

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Key facts

Who runs it
Denali Therapeutics Inc.
Where
Chapel Hill, Chicago, Cincinnati, Hackensack, Houston, Oakland, Philadelphia, and Salt Lake City, United StatesSee the 8 sitesAlso in 14 other countries, 25 sites
Trial code
Status
Enrolling by invitation
Phase
Phase 2/3
People taking part
99 people, planned
Started
20 Sept 2023
Expected to end
Jun 2027
Type of study
Interventional, 7 groups
Treatments tested
  • tividenofusp alfa
Record updated
9 November 2026

Who can take part

Age
Up to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • For participants from Study DNLI-E-0002 only: Completed at least through the Week 49 visit in Study DNLI-E-0002 and did not discontinue study intervention early
  • For participants from Study DNLI-E-0007 only: Completed the treatment period of 96 weeks in Cohort A for nMPS II participants and 48 weeks in Cohort B for nnMPS II participants

Who cannot take part

  • Unstable or poorly controlled medical condition(s) or significant medical or psychological comorbidity or comorbidities that, in the opinion of the investigator, would interfere with safe participation in the trial or interpretation of study assessments

Where in United States

Also in 14 other countries, 25 sites

  • UNC Children's Research InstituteChapel Hill, United StatesEnrolling by invitation
  • Ann and Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesEnrolling by invitation
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesEnrolling by invitation
  • Hackensack University Medical CenterHackensack, United StatesEnrolling by invitation
  • The University of Texas Medical School at HoustonHouston, United StatesEnrolling by invitation
  • UCSF Benioff Children's Hospital OaklandOakland, United StatesEnrolling by invitation
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesEnrolling by invitation
  • Huntsman Cancer HospitalSalt Lake City, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This is a multiregional open-label extension (OLE) to assess the safety, tolerability, and efficacy of long-term treatment with tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant intravenous (IV) enzyme replacement therapy (ERT) for Hunter syndrome (MPS II). Participants who complete at least through the Week 49 visit in Study DNLI-E-0002 and do not discontinue study intervention early and participants who complete Study DNLI-E-0007 will be enrolled in this OLE. All participants will receive DNL310 for up to 5 years from the time of entry in this OLE. Participants, site staff, and the Sponsor will remain blinded to the original treatment assignment for participants entering this OLE from Study DNLI-E-0007.

The 7 groups in the trial

  • Cohort A2Treatment being tested

    Participants with nMPS II, aged ≥5 to ≤10 years

    Treatment: tividenofusp alfa

  • Cohort B2Treatment being tested

    Participants with nMPS II or nnMPS II, aged ≥1 to ≤18 years

    Treatment: tividenofusp alfa

  • Cohort C2Treatment being tested

    Participants with nMPS II, aged \<4 years

    Treatment: tividenofusp alfa

  • Cohort D2Treatment being tested

    Participants with nMPS II or nnMPS II, aged ≤18 years with preexisting hepatomegaly who have never taken standard-of-care ERT

    Treatment: tividenofusp alfa

  • Cohort E2Treatment being tested

    Participants with nMPS II, aged ≥6 years; participants with nnMPS II, aged \<6 or ≥17 years; or participants with nMPS II, aged ≥1 to ≤18 years, with a history of prior HSCT or gene therapy and have completed at least 48 weeks in Study DNLI-E-0001

    Treatment: tividenofusp alfa

  • Cohort A7Treatment being tested

    Participants with nMPS II, aged ≥2 to \<6 years

    Treatment: tividenofusp alfa

  • Cohort B7Treatment being tested

    Participants with nnMPS II, aged ≥6 to \<17 years

    Treatment: tividenofusp alfa

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Patients With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
Record updated
9 November 2026